Henry Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Henry Rodriguez has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Ana I. Robles
National Cancer Institute 27 Rockville, MD
21 shared publications - Karsten Krug
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts
20 shared publications - Michael A. Gillette
Broad Institute of MIT and Harvard, Cambridge, MA, USA
20 shared publications - Shankha Satpathy
Broad Institute of MIT and Harvard, Cambridge, MA, USA
20 shared publications - Steven A. Carr
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
20 shared publications - Anh Minh Tran Huynh
Baylor College of Medicine 1 Lester and Sue Smith Breast Center Houston, Texas
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
CRDC Program Collaborator Names from NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessCRDC Program Collaborator Names from NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1. from NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
A list of web resources for CRDC data commons
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1. from NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
A list of web resources for CRDC data commons
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Cross referencing to genomic and imaging resources for individual cases. Example of cross-referencing (A) on the Clinical tab of PDC’s Explore page; B, on the Clinical tab and External References section of PDC study summary pages.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Cross referencing to genomic and imaging resources for individual cases. Example of cross-referencing (A) on the Clinical tab of PDC’s Explore page; B, on the Clinical tab and External References section of PDC study summary pages.
- Open Access
- 1 January 2025
- Published by Biophysical Society of China in Biophysics Reports
- Vol. 11 (1) , 56-76
Advancements in proteogenomics for preclinical targeted cancer therapy research
Advancements in molecular characterization technologies have accelerated targeted cancer therapy research at unprecedented resolution and dimensionality. Integrating comprehensive multi-omic molecular profiling of a tumor, proteogenomics, marks a transformative milestone for preclinical cancer research. In this paper, we initially provided an overview of proteogenomics in cancer research, spanning genomics, transcriptomics, and proteomics. Subsequently, the applications were introduced and examined from different perspectives, including but not limited to genetic alterations, molecular quantifications, single-cell patterns, different post-translational modification levels, subtype signatures, and immune landscape. We also paid attention to the combined multi-omics data analysis and pancancer analysis. This paper highlights the crucial role of proteogenomics in preclinical targeted cancer therapy research, including but not limited to elucidating the mechanisms of tumorigenesis, discovering effective therapeutic targets and promising biomarkers, and developing subtype-specific therapies.
- 1 January 2025
- Published by Biophysical Society of China in Biophysics Reports
- Vol. 11 (1) , 56-76
Open AccessAdvancements in proteogenomics for preclinical targeted cancer therapy research
Advancements in molecular characterization technologies have accelerated targeted cancer therapy research at unprecedented resolution and dimensionality. Integrating comprehensive multi-omic molecular profiling of a tumor, proteogenomics, marks a transformative milestone for preclinical cancer research. In this paper, we initially provided an overview of proteogenomics in cancer research, spanning genomics, transcriptomics, and proteomics. Subsequently, the applications were introduced and examined from different perspectives, including but not limited to genetic alterations, molecular quantifications, single-cell patterns, different post-translational modification levels, subtype signatures, and immune landscape. We also paid attention to the combined multi-omics data analysis and pancancer analysis. This paper highlights the crucial role of proteogenomics in preclinical targeted cancer therapy research, including but not limited to elucidating the mechanisms of tumorigenesis, discovering effective therapeutic targets and promising biomarkers, and developing subtype-specific therapies.
- Open Access
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
PDC study summary page offering a comprehensive overview of both data and metadata.
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
PDC study summary page offering a comprehensive overview of both data and metadata.
- Open Access
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Table 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Documentation resources in the PDC
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Documentation resources in the PDC
- Open Access
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Available data types in the proteomic data commons
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Available data types in the proteomic data commons
- Open Access
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Available data types in the proteomic data commons
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Available data types in the proteomic data commons
- Open Access
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Table 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Documentation resources in the PDC
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Documentation resources in the PDC
- Open Access
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
PDC study summary page offering a comprehensive overview of both data and metadata.
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
PDC study summary page offering a comprehensive overview of both data and metadata.